The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Intratumoral CpG, ibrutinib and radiotherapy in low-grade R/R follicular lymphoma
Tanaya Shree
• 2 Jul 2019
Tanaya Shree, MD, Stanford University Medical Center, California, CA, discusses the interim clinical and correlative results of the Phase I/II trial of the CpG TLR9 agonist SD-101, ibrutinib and radiation therapy in relapsed/refractory low-grade follicular lymphoma (NCT02927964). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
